GlassScriptPhysician profile
Pranava Ganesh
NPI 1952798712
$5,919.57
in general payments reported to CMS, 2019-2025
34 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.19 · 2020: $494 · 2021: $945 · 2022: $991 · 2023: $742 · 2024: $1,223 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392 · Entertainment: $36.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.71 |
| Entertainment | $36.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $755.29 | 2020-2025 | Farxiga, Brilinta, Wainua |
| Amgen INC. | $564.36 | 2020-2025 | Repatha, Repatha |
| Abiomed | $545.51 | 2022-2025 | Impella |
| Merck Sharp & Dohme LLC | $517.57 | 2021-2025 | Verquvo, Winrevair |
| Pfizer INC. | $498.71 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.03 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $445.95 | 2021-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $407.92 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $228.36 | 2022-2024 | |
| Chiesi USA, INC. | $156.53 | 2020-2025 | Juxtapid, Kengreal |
| Medtronic, INC. | $131.57 | 2021-2022 | |
| Amarin Pharma, INC. | $129.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $116.95 | 2024 | Xarelto |
| Allergan, INC. | $111.48 | 2019-2020 | |
| Bridgebio Pharma, INC. | $97.33 | 2025 | Attruby |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $96.85 | 2025 | |
| Alnylam Pharmaceuticals INC. | $83.05 | 2021-2024 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $67.52 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $59.92 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $50.15 | 2023 | Watchman Flx, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $49.69 | 2022-2025 | Evkeeza |
| Akcea Therapeutics, INC. | $47.01 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $41.71 | 2023-2024 | Inpefa |
| Stereotaxis INC | $36.19 | 2025 | Genesis |
| Haemonetics Corporation | $24.06 | 2022 | |
| Inari Medical, INC. | $22.62 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.08 | 2024 | Uptravi |
| Scpharmaceuticals INC. | $20.24 | 2025 | |
| Angiodynamics, INC. | $18.85 | 2025 | Alphavac |
| Daiichi Sankyo INC. | $18.60 | 2024 | Injectafer |
| Abbott Laboratories | $17.32 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.84 | 2021 | |
| Novo Nordisk INC | $14.96 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranava Ganesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.